OTCMKTS:BICX - Biocorrx Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.54 -0.45 (-9.02 %)
(As of 02/17/2019 04:00 PM ET)
Previous Close$4.54
Today's Range$4.54 - $4.62
52-Week Range$0.0410 - $0.2820
Volume6,717 shs
Average Volume130,455 shs
Market Capitalization$1.16 billion
P/E RatioN/A
Dividend YieldN/A
BioCorRx Inc., through its subsidiaries, provides alcoholism and opioid addiction treatment program for use in rehabilitation and treatment centers in the United States. The company distributes and licenses BioCorRx recovery program, a medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant. It is also developing BICX101, an injectable naltrexone product; and BICX102, an implantable naltrexone implant for the treatment of alcohol and opioid addiction. The company distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is headquartered in Anaheim, California.

Receive BICX News and Ratings via Email

Sign-up to receive the latest news and ratings for BICX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Specialty outpatient clinics, not elsewhere classified
Current SymbolOTCMKTS:BICX



Sales & Book Value

Annual Sales$650,000.00
Book Value($0.02) per share


Net Income$-29,700,000.00
Net Margins-1,144.56%


Market Cap$1.16 billion
OptionableNot Optionable

Biocorrx (OTCMKTS:BICX) Frequently Asked Questions

What is Biocorrx's stock symbol?

Biocorrx trades on the OTCMKTS under the ticker symbol "BICX."

How were Biocorrx's earnings last quarter?

Biocorrx Inc (OTCMKTS:BICX) issued its quarterly earnings data on Thursday, November, 17th. The company reported ($0.02) EPS for the quarter. The company earned $0.17 million during the quarter. View Biocorrx's Earnings History.

Has Biocorrx been receiving favorable news coverage?

News headlines about BICX stock have been trending negative recently, InfoTrie reports. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Biocorrx earned a coverage optimism score of -2.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future.

Who are some of Biocorrx's key competitors?

Who are Biocorrx's key executives?

Biocorrx's management team includes the folowing people:
  • Mr. Brady James Granier, Pres, CEO & Director (Age 46)
  • Ms. Lourdes Felix, CFO, COO & Director (Age 50)
  • Mr. Thomas Patrick Welch, VP of Operations
  • Dr. George N. Fallieras, Medical Consultant
  • Dr. David R. Gastfriend M.D., Medical Consultant

How do I buy shares of Biocorrx?

Shares of BICX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biocorrx's stock price today?

One share of BICX stock can currently be purchased for approximately $4.54.

How big of a company is Biocorrx?

Biocorrx has a market capitalization of $1.16 billion and generates $650,000.00 in revenue each year.

What is Biocorrx's official website?

The official website for Biocorrx is http://www.biocorrx.com.

How can I contact Biocorrx?

Biocorrx's mailing address is 2390 EAST ORANGEWOOD AVENUE SUITE 575, ANAHEIM CA, 92806. The company can be reached via phone at 714-462-4880 or via email at [email protected]

MarketBeat Community Rating for Biocorrx (OTCMKTS BICX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  53 (Vote Outperform)
Underperform Votes:  47 (Vote Underperform)
Total Votes:  100
MarketBeat's community ratings are surveys of what our community members think about Biocorrx and other stocks. Vote "Outperform" if you believe BICX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BICX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel